Results 171 to 180 of about 257,933 (304)

UBL5 and Its Role in Viral Infections

Unlike other ubiquitin-like family members, UBL5 is structurally and functionally atypical, and a novel role in various biological processes and diseases has been discovered.
Yanhua He, Xijia Feng, Yangang Liu, Zhongtian Qi, Xijing Qian, Liancheng Xia, Yifan Sui   +6 more
core   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

Hepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff, David Smookler, Mia J. Biondi, Scott Enman, Tintin Fuliang, Sana Mahmood, Agustina Crespi, Maria Marquez, Rafique Van Uum, Lucy You, Brett Wolfson‐Stofko, Renee Logan, Erin LeDrew, Hemant Shah, Harry Janssen, Camelia Capraru, Elisa Venier, Jordan J. Feld   +17 more
wiley   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review. [PDF]

Biomedicines, 2021
Raoufi E, Bahramimeimandi B, Salehi-Shadkami M, Chaosri P, Mozafari MR.   +4 more
europepmc   +1 more source

CRISPR Screen Reveals PACT as a Pro-Viral Factor for Dengue Viral Replication

The dengue virus is a single-stranded, positive-sense RNA virus that infects ~400 million people worldwide. Currently, there are no approved antivirals available.
Jan E. Carette, Wenjie Qiao, Peter Sarnow, Kuo-Feng Weng, Pavithra Umashankar, Shwetha Shivaprasad   +5 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Viral Vectors for Veterinary Vaccines

, 1999
Whatever strategy is adopted for the development of viral vectors for delivery of veterinary vaccines there are several key points to consider: (1) Will the vectored vaccine give a delivery advantage compared to what's already available? (2) Will the vectored vaccine give a manufacturing advantage compared to what's already available?
openaire   +2 more sources